cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy

References

• Barba AA, Bochicchio S, Dalmoro A, et al. (2019). Lipid delivery systems for nucleic-acid-based-drugs: from production to clinical applications. Pharmaceutics 11:360.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Roche B, Martienssen RA. (2019). RNA-induced initiation of transcriptional silencing (RITS) complex structure and function. RNA Biol 16:1133–46.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ji Y. (2019). RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur J Pharm Sci 128:8–17.
   PubMed Web of Science ®Google Scholar
• Chi Y, Yin X, Sun K, et al. (2017). Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release 261:113–25.
   PubMed Web of Science ®Google Scholar
• Diao L, Tao J, Wang Y, et al. (2019). Co-delivery of dihydroartemisinin and HMGB1 siRNA by TAT-modified cationic liposomes through the TLR4 signaling pathway for treatment of lupus nephritis. Int J Nanomedicine 14:8627–45.
   PubMed Web of Science ®Google Scholar
• Dong Y, Siegwart DJ, Anderson DG. (2019). Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 144:133–47.
   PubMed Web of Science ®Google Scholar
• Hajiasgharzadeh K, Somi MH, Shanehbandi D, et al. (2019). Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol 234:3263–76.
   PubMed Web of Science ®Google Scholar
• Han W, Yuan Y, Li H, et al. (2019). Design and anti-tumor activity of self-loaded nanocarriers of siRNA. Colloids Surf B Biointerfaces 183:110385.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Hardie J, Liu Y, et al. (2018). Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory treatment. J Control Release 283:235–40.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Xia ZL, Ze LJ, et al. (2020). Research progress of nucleic acid delivery vectors for gene therapy. Biomed Microdevices 22:16.
   PubMed Web of Science ®Google Scholar
• Jin L, Wang Q, Chen J, et al. (2019). Efficient delivery of therapeutic siRNA by Fe3O4 magnetic nanoparticles into oral cancer cells. Pharmaceutics 11:615.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Yamada Y, Harashima H. (2018). Optimization of siRNA delivery to target sites: issues and future directions. Expert Opin Drug Deliv 15:1053–65.
   PubMed Web of Science ®Google Scholar
• Khan AA, Alanazi AM, Jabeen M, et al. (2019). Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice. Sci Rep 9:15825.
   PubMed Web of Science ®Google Scholar
• Kozielski KL, Tzeng SY, De Mendoza BA, et al. (2014). Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells. ACS Nano 8:3232–41.
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Witzigmann D, Chen S, et al. (2019). Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res 52:2435–44.
   PubMed Web of Science ®Google Scholar
• Ma D. (2014). Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 6:6415–25.
   PubMed Web of Science ®Google Scholar
• Mainini F, Eccles MR. (2020). Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules 25:2692.
   PubMed Web of Science ®Google Scholar
• Pezzoli D, Tallarita E, Rosini E, et al. (2016). Characterization and investigation of redox-sensitive liposomes for gene delivery. Methods Mol Biol 1445:217–33.
   PubMedGoogle Scholar
• Sasayama Y, Hasegawa M, Taguchi E, et al. (2019). In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors. J Control Release 311–312:245–56.
   PubMed Web of Science ®Google Scholar
• Scarabel L, Perrone F, Garziera M, et al. (2017). Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. Expert Opin Drug Deliv 14:797–810.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. (2019). The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421–46.
   PubMed Web of Science ®Google Scholar
• Su C. (2016). Survivin in survival of hepatocellular carcinoma. Cancer Lett 379:184–90.
   PubMed Web of Science ®Google Scholar
• Subhan MA, Torchilin VP. (2019). Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res 214:62–91.
   PubMed Web of Science ®Google Scholar
• Tang X, Zhou S, Tao X, et al. (2017). Targeted delivery of docetaxel via Pi-Pi stacking stabilized dendritic polymeric micelles for enhanced therapy of liver cancer. Mater Sci Eng C Mater Biol Appl 75:1042–8.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Wang Z, et al. (2019). A thermosensitive gel based on w1/o/w2 multiple microemulsions for the vaginal delivery of small nucleic acid. Drug Deliv 26:168–78.
   PubMed Web of Science ®Google Scholar
• Wu CH, Chen CY, Yeh CT, et al. (2020). Radiosensitization of hepatocellular carcinoma through targeting radio-associated microRNA. Int J Mol Sci 21:1859.
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. (2020). New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 371:m3544.
   PubMed Web of Science ®Google Scholar
• Yang S, Lee RJ, Yang X, et al. (2015). A novel reduction-sensitive modified polyethylenimine oligonucleotide vector. Int J Pharm 484:44–50.
   PubMed Web of Science ®Google Scholar
• Yang S, Wang D, Sun Y, et al. (2019). Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide. Drug Deliv 26:965–74.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yang S, Tian Q, et al. (2019). Delivery of antisense oligonucleotide LOR-2501 using transferrin-conjugated polyethylenimine-based lipid nanoparticle. Anticancer Res 39:1785–93.
   PubMed Web of Science ®Google Scholar